Characteristics of MAC and RIC recipients and donors
| . | MAC . | RIC . | Donors . |
|---|---|---|---|
| Number of recipients | 30 | 33 | 64 |
| Number of centers | 10 | 11 | 12 |
| Age at transplant, median (range), y | 51 (23-62) | 62 (19-69) | 56 (18-65) |
| Sex, n (%) | |||
| Male | 16 (53) | 24 (73) | 41 (64) |
| Female | 14 (47) | 9 (27) | 23 (36) |
| Donor-recipient sex match, n (%) | |||
| Female-male | 6 (20) | 7 (21) | |
| Other | 24 (80) | 26 (79) | |
| Karnofsky performance status, n (%) | |||
| 90-100 | 20 (67) | 15 (45) | |
| ≤80 | 10 (33) | 18 (55) | |
| HCT-CI, n (%) | |||
| 0 | 5 (17) | 9 (27) | |
| 1 | 8 (27) | 6 (18) | |
| 2 | 6 (20) | 2 (6) | |
| 3 | 6 (20) | 4 (12) | |
| ≥4 | 5 (13) | 12 (36) | |
| Recipient CMV serostatus, n (%) | |||
| Negative | 15 (50) | 7 (21) | |
| Positive | 14 (47) | 25 (76) | |
| Inconclusive or unknown | 1 (3) | 1 (3) | |
| Recipient diagnosis, n (%) | |||
| AML | 12 (40) | 11 (33) | |
| ALL | 8 (27) | 2 (6) | |
| CML | 3 (10) | — | |
| MDS | 4 (13) | 11 (33) | |
| Lymphoma | 3 (10) | 9 (27) | |
| Disease risk index | |||
| Low, n (%) | 4 (14) | 5 (17) | |
| Intermediate, n (%) | 19 (66) | 19 (63) | |
| High, n (%) | 3 (10) | 6 (20) | |
| Very high, n (%) | 3 (10) | 0 | |
| Unknown, n | 1 | 3 | |
| Conditioning, n (%) | |||
| Busulfan/cyclophosphamide | 15 (50) | — | |
| Busulfan/fludarabine (MAC) | 5 (17) | — | |
| Cyclophosphamide/TBI | 8 (27) | — | |
| Etoposide/TBI | 2 (7) | — | |
| Melphalan/fludarabine | — | 7 (21) | |
| Busulfan/fludarabine (RIC) | — | 25 (76) | |
| Cyclophosphamide/fludarabine/TBI | — | 1 (3) | |
| GVHD prophylaxis, n (%) | |||
| CNI + MTX based | 24 (80) | 24 (70) | |
| CNI + MMF based | 3 (10) | 5 (15) | |
| CNI + others | — | 3 (9) | |
| CNI alone | 3 (10) | — | |
| Other | — | 1 (3) | |
| Use of post-HCT GCSF, n (%) | |||
| Yes | 22 (73) | 16 (48) | |
| No | 8 (27) | 17 (52) |
| . | MAC . | RIC . | Donors . |
|---|---|---|---|
| Number of recipients | 30 | 33 | 64 |
| Number of centers | 10 | 11 | 12 |
| Age at transplant, median (range), y | 51 (23-62) | 62 (19-69) | 56 (18-65) |
| Sex, n (%) | |||
| Male | 16 (53) | 24 (73) | 41 (64) |
| Female | 14 (47) | 9 (27) | 23 (36) |
| Donor-recipient sex match, n (%) | |||
| Female-male | 6 (20) | 7 (21) | |
| Other | 24 (80) | 26 (79) | |
| Karnofsky performance status, n (%) | |||
| 90-100 | 20 (67) | 15 (45) | |
| ≤80 | 10 (33) | 18 (55) | |
| HCT-CI, n (%) | |||
| 0 | 5 (17) | 9 (27) | |
| 1 | 8 (27) | 6 (18) | |
| 2 | 6 (20) | 2 (6) | |
| 3 | 6 (20) | 4 (12) | |
| ≥4 | 5 (13) | 12 (36) | |
| Recipient CMV serostatus, n (%) | |||
| Negative | 15 (50) | 7 (21) | |
| Positive | 14 (47) | 25 (76) | |
| Inconclusive or unknown | 1 (3) | 1 (3) | |
| Recipient diagnosis, n (%) | |||
| AML | 12 (40) | 11 (33) | |
| ALL | 8 (27) | 2 (6) | |
| CML | 3 (10) | — | |
| MDS | 4 (13) | 11 (33) | |
| Lymphoma | 3 (10) | 9 (27) | |
| Disease risk index | |||
| Low, n (%) | 4 (14) | 5 (17) | |
| Intermediate, n (%) | 19 (66) | 19 (63) | |
| High, n (%) | 3 (10) | 6 (20) | |
| Very high, n (%) | 3 (10) | 0 | |
| Unknown, n | 1 | 3 | |
| Conditioning, n (%) | |||
| Busulfan/cyclophosphamide | 15 (50) | — | |
| Busulfan/fludarabine (MAC) | 5 (17) | — | |
| Cyclophosphamide/TBI | 8 (27) | — | |
| Etoposide/TBI | 2 (7) | — | |
| Melphalan/fludarabine | — | 7 (21) | |
| Busulfan/fludarabine (RIC) | — | 25 (76) | |
| Cyclophosphamide/fludarabine/TBI | — | 1 (3) | |
| GVHD prophylaxis, n (%) | |||
| CNI + MTX based | 24 (80) | 24 (70) | |
| CNI + MMF based | 3 (10) | 5 (15) | |
| CNI + others | — | 3 (9) | |
| CNI alone | 3 (10) | — | |
| Other | — | 1 (3) | |
| Use of post-HCT GCSF, n (%) | |||
| Yes | 22 (73) | 16 (48) | |
| No | 8 (27) | 17 (52) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; CNI, calcineurin inhibitor; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate.